Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Company Overview

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases.

Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling. The company has evaluated tegoprubart in clinical programs involving kidney transplantation, islet-cell transplantation and amyotrophic lateral sclerosis, and continues to investigate its potential in transplantation and other immune-mediated conditions.

The company was formerly known as Novus Therapeutics, Inc. and adopted the name Eledon Pharmaceuticals, Inc. in 2020. Eledon is headquartered in Irvine, California, and does not currently have a marketed commercial product; its activities primarily involve research, clinical development and collaboration with medical and scientific institutions.

Key Stats

• Today's Range: $2.22 to $2.44
• 50-Day Range: $2.13 to $3.62
• 52-Week Range: $1.35 to $4.60
• Volume: 935,234 shs
• Average Volume: N/A
• Market Capitalization: $195.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Eledon Pharmaceuticals Stock Analysis - MarketRank™

Eledon Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 740th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Eledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Eledon Pharmaceuticals has a consensus price target of $10.00, representing about 314.9% upside from its current price of $2.41.

Amount of Analyst Coverage

Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eledon Pharmaceuticals is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eledon Pharmaceuticals is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.75% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 10.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently increased by 0.63%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eledon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eledon Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.41

News Sentiment

Eledon Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

3 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of Eledon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/28/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELDN
• CIK: 1404281
• Web: www.eledon.com
• Phone: (949) 238-8090
• Fax: N/A
• Employees: 33
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Eledon Pharmaceuticals: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +314.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 81,261,000
• Free Float: 73,460,000
• Market Cap: $195.84 million
• Optionable: Optionable
• Beta: 0.84